ARWR Stock — Arrowhead Pharmaceuticals Inc.: Cash, EV, Pipeline

Share price

$66.48

Market cap

$9,390.6M

Cash

$1,602.0M

Enterprise value

$7,788.6M

Balance sheet

Cash	$1,602.0M
Debt	$0.0M
Net cash	$1,602.0M
Enterprise value	$7,788.6M
Basic shares	141.1M shares
Fully diluted shares	155.9M shares
Fully diluted market cap	$10,361.0M
Cash per share	$11.35

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ARWR daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 30, 2026	Azithromycin Pill	Phase 1	Infections	—
Nov 11 - Dec 23	ARO-DIMERPA	Phase 2	Hyperlipidemia; Mixed	—
Jan 12 - Feb 23	ARO-ATXN2 Injection	Phase 1	Spinocerebellar Ataxia Type 2	—
Mar 15 - Apr 26	ARO-ALK7	Phase 2	Obesity; Diabetes Mellitus, Type 2	—
Jul 13 - Aug 24	ARO-MAPT-SC	Phase 2	Alzheimer Disease; Alzheimer Disease, Early Onset	—
Oct 1 - Nov 12	zodasiran Injection	Phase 3	Homozygous Familial Hypercholesterolemia	—
Oct 29 - Dec 10	ARO-INHBE	Phase 2	Obesity	—
Jan 12 - Feb 23	ARO-RAGE	Phase 2	Asthma	—
Aug 12 - Sep 23	Plozasiran Injection	Phase 3	Hypertriglyceridemia	—
Aug 12 - Sep 23	Zodasiran	Phase 3	Homozygous Familial Hypercholesterolemia	—
Aug 12 - Sep 23	ARO-033	Phase 1	Age-related Macular Degeneration	—
Apr 12 - May 24	Plozasiran	Phase 3	Severe Hypertriglyceridemia	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

REDEMPLO

Approved · Active Modality: siRNA

Aliases plozasiran

Target APOC3

Partnerships Sanofi (Genzyme): acquired Visirna HK assets (Aug 1, 2025) incl. Greater China rights; $130M upfront + $10M milestone on NMPA approval (Q2 FY2026); royalties on Greater China sales; supply purchase option

Indications

Reduction of triglycerides (NMPA-approved, China) (Approved)
Severe hypertriglyceridemia (sHTG) (Stage not disclosed)

Status note NMPA approval in China triggered a $10M milestone in Q2 FY2026.

Daplusiran/tomligisiran

Phase 2 · Active Modality: subcutaneously administered RNAi

Aliases GSK5637608, JNJ-3989

Target HBV

Partnerships GSK: worldwide exclusive license (GSK-HBV Agreement, Dec 11, 2023); $2.7M on signing; $2.5M milestone on dosing of fifth patient in Phase 2 (Dec 2024)

Indications

Chronic hepatitis B virus infection (Phase 2)

Status note Third-generation subcutaneously administered RNAi therapeutic.

Olpasiran

Stage not disclosed · Active Modality: siRNA

Aliases ARO-LPA

Target lipoprotein(a)

Partnerships Amgen: wholly responsible for clinical development and commercialization (Olpasiran Agreement, Sep 2016); Royalty Pharma: owns Amgen royalties; Arrowhead eligible for up to $485M in remaining milestones

Status note siRNA originally developed by Arrowhead, licensed to Amgen.

ARO-DM1

Stage not disclosed · Active Modality: RNAi

Target DMPK

Status note Second of two $200M development milestone payments earned Nov 2025 (received Jan 2026); first $50M annual fee installment earned and received Feb 2026.

ARO-PNPLA3

Stage not disclosed · Active

Target PNPLA3

Partnerships Madrigal: exclusive global license to develop, manufacture and commercialize (Madrigal License Agreement, May 4, 2026); $25M upfront (Jun 2, 2026), up to $975M milestones

Status note Clinical-stage program.

ARO-SNCA

Preclinical · Active

Target alpha-synuclein

Partnerships Novartis: exclusive worldwide license for ARO-SNCA preclinical program (Novartis Collaboration Agreement, Aug 29, 2025); Arrowhead performs certain R&D

Indications

Rare genetic diseases of the CNS (Preclinical)

Status note Part of Novartis collaboration covering multiple preclinical programs in rare genetic CNS diseases.

Sarepta collaboration programs

Stage not disclosed · Active

Partnerships Sarepta: Exclusive License and Collaboration Agreement (Nov 25, 2024) for multiple clinical and preclinical programs in rare genetic diseases of muscle, CNS and other tissues

Status note Individual program names not disclosed in excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	zodasiran Injection
Lead indication	Homozygous Familial Hypercholesterolemia
Lead phase	Phase 3
Active trials	15
Collaborator trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07037771	Phase 3	Active, not recruiting	Sponsor	ARWR	—	Homozygous Familial Hypercholesterolemia	—
NCT06822790	Phase 3	Recruiting	Sponsor	ARWR	—	Hypertriglyceridemia	—
NCT07473843	Phase 3	Not yet recruiting	Sponsor	ARWR	—	Homozygous Familial Hypercholesterolemia	—
NCT06880770	Phase 3	Recruiting	Sponsor	ARWR	—	Severe Hypertriglyceridemia	—
NCT06347133	Phase 3	Active, not recruiting	Sponsor	ARWR	—	Hypertriglyceridemia	—
NCT06347003	Phase 3	Active, not recruiting	Sponsor	ARWR	—	Severe Hypertriglyceridemia	—
NCT06347016	Phase 3	Active, not recruiting	Sponsor	ARWR	—	Severe Hypertriglyceridemia	—
NCT07223658	Phase 2	Recruiting	Sponsor	ARWR	—	Hyperlipidemia; Mixed	—
NCT06937203	Phase 2	Recruiting	Sponsor	ARWR	—	Obesity; Diabetes Mellitus, Type 2	—
NCT07221344	Phase 2	Recruiting	Sponsor	ARWR	—	Alzheimer Disease; Alzheimer Disease, Early Onset	—
NCT06700538	Phase 2	Recruiting	Sponsor	ARWR	—	Obesity	—
NCT07241546	Phase 2	Recruiting	Sponsor	ARWR	—	Asthma	—

Sponsor-matched active trials from ClinicalTrials.gov (15 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 18 active trials for Arrowhead Pharmaceuticals on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	1,992,783	no change	0.81%	2026-08-14
ADAR1 Capital Management	79,800	-500	0.32%	2026-08-14
Ikarian Capital	38,278	+38,278	0.51%	2026-08-14
RTW Investments	0	-585,682	0.00%	2026-08-14
Braidwell LP	0	-2,250,000	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ARWR — Arrowhead Pharmaceuticals Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders